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CortexThe role of peroxisome proliferator activator receptor (PPAR)β/δ in the pathogenesis of Alzheimer's disease has
only recently been explored through the use of PPARβ/δ agonists. Here we evaluated the effects of PPARβ/δ de-
ﬁciency on the amyloidogenic pathway and tau hyperphosphorylation. PPARβ/δ-null mice showed cognitive im-
pairment in the object recognition task, accompanied by enhanced DNA-binding activity of NF-κB in the cortex
and increased expression of IL-6. In addition, two NF-κB-target genes involved in β-amyloid (Aβ) synthesis and
deposition, the β site APP cleaving enzyme 1 (Bace1) and the receptor for advanced glycation endproducts
(Rage), respectively, increased in PPARβ/δ-null mice compared to wild type animals. The protein levels of glial
ﬁbrillary acidic protein (GFAP) increased in the cortex of PPARβ/δ-null mice, which would suggest the presence
of astrogliosis. Finally, tau hyperphosphorylation at Ser199 and enhanced levels of PHF-tauwere associatedwith
increased levels of the tau kinases CDK5 and phospho-ERK1/2 in the cortex of PPARβ/δ−/−mice.
Collectively, our ﬁndings indicate that PPARβ/δ deﬁciency results in cognitive impairment associated with
enhanced inﬂammation, astrogliosis and tau hyperphosphorylation in the cortex.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is themost common cause of dementia and
affects up to one-third of individuals who reach the age of 80 [1]. The AD
brain is characterized by two pathological hallmarks. The main histolog-
ical ﬁnding in AD is the accumulation of extracellular senile plaques
consisting mainly of β-amyloid (Aβ). Plaque-associated Aβ is generated
following cleavage of the amyloid precursor protein (APP) by β site APP
cleaving enzyme 1 (BACE1) [2] and γ-secretase [3]. BACE1 appears to
be the only β-secretase responsible for Aβ generation, as BACE1-
deﬁcient mice do not generate Aβ [4]. The second pathohistological fea-
ture of AD is the intracellular accumulation of neuroﬁbrillary tangles
(NFT). TheseNFT consist of tau oligomers, termedpairedhelicalﬁlaments
(PHF), an abnormally phosphorylated form of tau protein [5].
Hyperphosphorylation of tau protein results in neuronal degenerationacultat de Farmàcia, Diagonal
ax: +34 93 4035982.
ez-Carrera).
rights reserved.through deleterious effects on axonal transport mechanisms and cell
shape [6,7]. Several kinases phosphorylate tau protein, for example
cyclin-dependent kinase 5 (CDK5), casein kinase 1, extracellular
signal-regulated kinase (ERK) 1/2 and glycogen synthase kinase 3 β
(GSK-3β) [8–10].
Advanced glycation endproducts (AGE) and their receptor RAGE
are involved in various pathological conditions, especially diabetes
mellitus and insulin resistance [11], but they also play an important
role in the pathogenesis of AD [12]. RAGE is a multiligand receptor
that binds AGE, as well as Aβ, and may contribute to AD pathogenesis
by inﬂuencing the transport of Aβ into the brain or by modulating in-
ﬂammatory mechanisms through the NF-κB pathway [13–15].
In fact, in addition to neurodegeneration, AD also shows a signiﬁcant
inﬂammatory component [16] and epidemiological studies have re-
vealed that the use of non-steroidal anti-inﬂammatory drugs (NSAIDs)
dramatically reduce the risk for AD [17], suggesting that anti-
inﬂammatory treatments could be beneﬁcial to AD patients. This in-
ﬂammatory process involves NF-κB activation in the brains of AD pa-
tients [18]. Both BACE1 [19] and RAGE [20] are under the
transcriptional control of NF-κB.
Fig. 1. The PPARβ/δ-nullmouse shows cognitive impairment in the object recognition test
(ORT). Discrimination index (DI) of the two groups with bars indicating the mean ±
S.E.M. of eight mice. Wild type (WT) mice show preference for the novel object, while
PPARβ/δ−/− mice fail to exhibit discrimination between the two objects (⁎⁎P b 0.01,
one-sample t-test for mean different from zero). The graphic also show a higher DI for
WT compared to PPARβ/δ−/− animals (##P b 0.01 vs. wild-type mice, Student's t-test).
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(PPARδ) activation has been proposed as a potential treatment for insulin
resistance and metabolic syndrome [21]. In addition, due to its anti-
inﬂammatory and metabolic effects, activation of this nuclear receptor
may also regulate different aspects of AD [22]. In fact, two studies have
reported that PPARβ/δ agonists can be neuroprotective in AD [23,24].
The aim of this study was to examine how PPARβ/δ deﬁciency affects
the pathological pathways involved in the development of AD. Our ﬁnd-
ings demonstrate that PPARβ/δ-null mice show cognitive impairment in
the object recognition test (ORT), along with increased BACE1 and
RAGE levels, NF-κB DNA-binding activity, glial ﬁbrillary acidic protein
(GFAP) levels and tau hyperphosphorylation. These data suggest that
PPARβ/δ activation can prevent cognitive impairment as well as the de-
velopment of inﬂammation and tau hyperphosphorylation in the cortex.
2. Methods
2.1. Animals
The generation of PPARβ/δ-null mice was as described previously
[25]. Tenmale PPARβ/δ-null mice and 10 of their control male PPARβ/
δ wild type mice with the same genetic background (C57BL/6X129/Fig. 2. The PPARβ/δ-null mice show increased BACE1 mRNA and protein levels in the cortex
δ−/−mice. The graphics represent the quantiﬁcation of the Aprt-normalized mRNA levels, ex
ysis with antibodies against BACE1 and β-actin. Quantiﬁcation of band density normalized t
mice. Dividing lines indicate grouping of images from different parts of the same gel.SV) were used (aged 5–6 months old). The mice were housed under
standard light–dark cycle (12-h light/dark cycle) and temperature
(21 ± 1 °C) conditions, in accordance with the guidelines speciﬁed
by the University of Barcelona veterinary ofﬁce. Food and water
were available ad libitum. All procedures were approved by the Uni-
versity of Barcelona Bioethics Committee, as stated in Law 5/21 of
July 1995 passed by the Generalitat de Catalunya (Autonomous Gov-
ernment of Catalonia).
2.2. Object recognition test
The object recognition test (ORT) was conducted in a black-colored
two arm maze (25 × 5 × 20 cm). The maze was illuminated from
above and the light intensity in the center of the maze was 30 lx. The
objects for exploration were plastic ﬁgures (object A was 5.25 cm
high, and object B was 4.75 cm high). The maze, surface and objects
were cleaned with 96% ethanol between trials to eliminate olfactory
cues. Ten mice were habituated for three days in one 10-min session
every day in the empty maze, to habituate them to the apparatus and
test room. On the fourth day, each animalwas subjected to a 10-min ac-
quisition trial, during which they were placed in the maze in the pres-
ence of two identical objects (A + A or B + B) situated at the ends of
each arm. After a 2-h retention interval, the mice were placed in the
maze again and exposed to the familiar object and to a new object
(A + B or B + A) for a further 10 min. The total time spent exploring
each of the two objects was recorded. A discrimination index (DI) was
deﬁned as (tnew − told)/(tnew + told).
2.3. Tissue processing
All the animals were deeply anesthetized, the brain was removed
and the entire cortex was collected from 5 animals of each group and
ﬂash-frozen with liquid nitrogen and stored at −80 °C until homog-
enization. The other 3 brains of each group were removed, the cortex
of the right hemispheres was processed as before and the left hemi-
spheres were snap frozen by immersion in isopentane chilled in dry
ice and stored at −80 °C. The left hemispheres were cut at
20-μm-thick sections on a cryostat at −18 °C and placed on slides.. A, Analysis of the mRNA levels of Bace1 from the cortex of wild type (WT) or PPARβ/
pressed as means ± SD of six mice. B, Cell lysates were assayed for Western-blot anal-
o β-actin is also shown. Bars are the means ± ± SD of six mice. ⁎P b 0.05 vs. wild type
Fig. 3. The PPARβ/δ-null mice show increased RAGE mRNA and protein levels in the cortex. A, Analysis of the mRNA levels of Rage from the cortex of wild type (WT) or PPARβ/δ−/−
mice. The graphics represent the quantiﬁcation of the Aprt-normalized mRNA levels, expressed as means ± SD of six mice. B, Cell lysates were assayed for Western-blot analysis
with antibodies against RAGE and β-actin. Quantiﬁcation of band density normalized to β-actin is also shown. Bars are the means ± SD of six mice. ⁎P b 0.05 vs. wild type mice.
Dividing lines indicate grouping of images from different parts of the same gel.
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2.4. RNA preparation and quantitative RT-PCR
The relative levels of speciﬁc mRNAs were assessed by real-time
reverse transcription-polymerase chain reaction (RT-PCR), as de-
scribed previously [26]. The sequences of the forward and reverse
primers are shown in Supplementary Table 1.Fig. 4. The PPARβ/δ-null mice show increased NF-κB DNA-binding activity in the cortex. Anal
(WT) or PPARβ/δ−/− mice. The graphics represent the quantiﬁcation of the Aprt-normali
performed with a 32P-labeled NF-κB nucleotide and nuclear protein extracts (NE). Two s
probe, are shown. An analysis performed by incubating NE with an antibody directed again2.5. Isolation of nuclear extracts and electrophoretic mobility shift
assay (EMSA)
Nuclear extracts were isolated as previously described [27]. EMSA
was performed using double-stranded oligonucleotides (Promega,
Madison, WI) for the consensus binding site of the NF-κB nucleotide
(5′-AGTTGAGGGGACTTTCCCAGGC-3′). Oligonucleotides were labeled
in the following reaction: 2 μl of oligonucleotide (1.75 pmol/μl), 2 μl
of 5× kinase buffer, 1 μl of T4 polynucleotide kinase (10 U/μl)ysis of the mRNA levels of IL-6 (A), Tnf-α (B) andMcp-1 (C) from the cortex of wild type
zed mRNA levels, expressed as means ± SD of six mice. D, Autoradiograph of EMSA
peciﬁc complexes (I and II), based on competition with a molar excess of unlabeled
st the p65 subunit of NF-κB and Oct-1 are also shown. ⁎P b 0.05 vs. wild type mice.
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(3000 Ci/mmol at 10 mCi/ml) (Perkin Elmer, Waltham, MA), incubat-
ed at 37 °C for 1 h. The reaction was stopped by adding 90 μl of TE
buffer (10 mM Tris–HCl pH 7.4 and 1 mM EDTA). To separate the la-
beled probe from the unbound ATP, the reaction mixture was eluted
in a Nick column (GE Healthcare, CA) following the manufacturer's
instructions. Eight micrograms of crude nuclear protein were incubat-
ed for 10 min on ice in binding buffer (10 mM Tris–HCl pH 8.0,
25 mM KCl, 0.5 mM DTT, 0.1 mM EDTA pH 8.0, 5% glycerol, 5 mg/ml
BSA, and 50 μg/ml poly(dI–dC)), in a ﬁnal volume of 15 μl. Labeled
probe (approximately 60,000 cpm) was added and the reaction was
incubated for 15 min at 4 °C. Where indicated, speciﬁc competitor
oligonucleotide was added before the labeled probe and incubated for
10 min on ice. Protein–DNA complexes were resolved by electrophore-
sis at 4 °C on a 5% acrylamide gel and subjected to autoradiography.
2.6. Antibodies and immunoblotting
Antibodies against total and phospho-ERK1/2, total and phospho-Akt,
total and phospho-GSK3β and p25 were purchased from Cell Signaling
(Danvers, MA). Antibody against CDK5 was purchased from Santa Cruz
(Santa Cruz, CA). Total and phosphoTau-Ser199 antibodies were pur-
chased fromBiosource (Paisley, UK), Cd11b andGFAP fromAbcam (Cam-
bridge, UK), Iba-1 from Wako (Osaka, Japan), BACE1 antibody from
Millipore (Billerica, MA), RAGE antibody from R&D Systems (Minneapo-
lis, MN) and PHF from Thermo Scientiﬁc (Waltham, MA) and AlexaFluor
546 donkey anti-rabbit IgG from Invitrogen (Barcelona, Spain). Cortical
tissue was lysed in RIPA buffer (Sigma, St Louis, MO) with phosphatase
and protease inhibitors (0.2 mM phenylmethylsulfonyl ﬂuoride, 1 mM
sodium orthovanadate, 5.4 μg/ml aprotinin). The homogenate was
centrifuged at 16,700 ×g for 30 min at 4 °C. Protein concentration was
measured using the Bradford method.
Proteins from whole-tissue lysates and nuclear extracts were sepa-
rated by SDS–PAGE, then transferred to immobilon polyvinylidene
diﬂuoride membranes (Millipore) and blotted with various antibodies
(as speciﬁed in “Results section”). Detection was achieved using an
EZ-ECL chemiluminescence kit (Amersham, Pittsburgh, PA). The size
of detected proteins was estimated using protein molecular-mass stan-
dards (Invitrogen, Barcelona, Spain).
2.7. Immunohistochemistry and image acquisition
Brain slides were allowed to defreeze at room temperature for 2 h
and rehydrated with PBS for 5 min before being blocked and perme-
abilized with PBS containing 1% BSA and 0.1% Triton-X-100
(Sigma-Aldrich) for 20 min. Brain sections were then washed twice
for 5 min in PBS and incubated with the primary antibody (see
Results section) overnight at 4 °C. Slides were washed again twice
for 5 min and incubated with the secondary antibody for 1 h at
room temperature. Finally, slides were washed, mounted using
ﬂuoromount G, allowed to dry overnight at room temperature and
stored at 4 °C in the dark. Immunostained controls were performed
by incubation with PBS instead of the primary antibody and/or sec-
ondary antibody. Images were taken with a ﬂuorescence laser micro-
scope (BX41, Olympus, Germany) at 20× magniﬁcation.
2.8. Statistical analyses
Data are presented as mean ± SD or S.E.M. of 6 to 10 separate an-
imals. In the ORT, the one-sample t test was used to examine whetherFig. 5. The PPARβ/δ-nullmice show increasedGFAP protein levels in the cortex. A, Cellular extracts
Cd11b (OX42) andβ-actin antibodies as indicated. Bars are themeans ± SDof sixmice. B, Analysis
mRNA levels, expressed as means ± SD of six mice. C, Representative images of Iba-1 of the corte
alyzed byWestern blotwith GFAP and β-actin antibodies. Quantiﬁcation of band density normalize
Dividing lines indicate grouping of images from different parts of the same gel. E, Representativesingle columns were different from zero. Signiﬁcant differences in the
other data were analyzed by the Student's t-test using the GraphPad
InStat program (GraphPad Software V3.05) (GraphPad Software Inc.,
San Diego, CA). Differences were considered signiﬁcant at P b 0.05.
3. Results
3.1. Cognitive function
We ﬁrst conﬁrm the absence of PPARβ/δ expression in the cortex
of our mouse model (Supplementary Fig. 1A), whereas the expression
of either PPARα (Supplementary Fig. 1B) or PPARγ (Supplementary
Fig. 1C) was not affected. PPARβ/δ inﬂuences running endurance
[28] and this can lead to misinterpretation of the Morris water maze
test. Thus, we tested learning and recognition memory in PPARβ/
δ−/− and wild type mice by using the ORT. If mice remember an ini-
tial encounter with a new object, they tend to preferentially explore
the new object over the familiar object, typically quantiﬁed as the
DI [29]. In the ORT we found that, while PPARβ/δ-deﬁcient mice failed
to show discrimination between the two objects, since their DI was
not different from zero (P > 0.05), wild type animals spent more
time exploring the new object (P b 0.01) (Fig. 1). Moreover, a com-
parison between the two groups revealed that their performance in
the ORT differed, as PPARβ/δ-deﬁcient mice showed a lower DI com-
pared to age-matched wild type (P b 0.01) (Fig. 1).
3.2. PPARβ/δ-deﬁcient mice show increased BACE1 and RAGE levels
Next we examined whether PPARβ/δ deﬁciency affected BACE1
levels. In the cortical tissue of PPARβ/δ-null mice we observed a 2-fold
increase (P b 0.05) in Bace1 mRNA levels compared to wild type mice
(Fig. 2A). In agreement with this, BACE1 protein levels were 4.5-fold
higher (P b 0.05) in PPARβ/δ−/− mice than in wild type animals
(Fig. 2B).
Interestingly, RAGE signaling contributes to the pathogenesis of an
inﬂammatory response that ultimately impairs neuronal function and
directly affects Aβ accumulation [30]. In the cortex of PPARβ/δ-null
mice we observed an increase in the mRNA levels of Rage (1.7-fold in-
duction, P b 0.05) compared to wild type mice, which was consistent
with an increase (2-fold induction, P b 0.05) in the protein levels of
this receptor (Fig. 3A and B).
Since Aβ is generated following APP cleavage by BACE1 and RAGE
favors its transport into the brain, we evaluated Aβ-pathology by
Aβ1–42 sandwich ELISA and immunohistochemistry. We did not de-
tect Aβ1–42 levels in the cortex of either PPARβ/δ-null or wild type
mice (data not shown). These ﬁndings suggest that, at this stage, Aβ
deposits do not contribute to the cognitive impairment observed in
PPARβ/δ-deﬁcient mice.
3.3. Increased NF-κB DNA-binding activity in the cortex of PPARβ/δ-null mice
Since we have previously reported increased NF-κB activity in
white adipose tissue of PPARβ/δ-deﬁcient mice [31], we explored
whether the activity of this pro-inﬂammatory transcription factor
was enhanced in the cortex. First, we assessed the mRNA levels of
several NF-κB-target genes. The transcript levels of IL-6 (2.2-fold in-
duction, P b 0.05), Tnf-α (5.5-fold induction) and Mcp-1 (3-fold in-
duction) were higher in the cortex of PPARβ/δ−/− mice compared
to wild type mice, although due to the high level of inter-individual
variability, only the differences for IL-6 were statistically signiﬁcantfrom the cortex ofwild type (WT) or PPARβ/δ-nullmicewere analyzed byWestern blotwith
of themRNA levels of F4/80. The graphics represent the quantiﬁcation of theAprt-normalized
x tissue. D, Cellular extracts from the cortex of wild type (WT) or PPARβ/δ−/−mice were an-
d toβ-actin is also shown. Bars are themeans ± SD of sixmice. ⁎P b 0.05 vs. wild typemice.
images of GFAP of the cortex tissue.
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cortex of PPARβ/δ-null mice compared to wild type animals, we
performed an EMSA. The NF-κB probe formed two complexes (I and
II) with nuclear proteins (Fig. 4D). Speciﬁcity of the DNA-binding
complexes was assessed in competition experiments by adding an ex-Fig. 6. The PPARβ/δ-null mice show increased tau hyperphosphorylation in the cortex.
Cellular extracts from the cortex of wild type (WT) or PPARβ/δ−/−mice were analyzed
by Western blot with total and phospho-GSK-3β-Ser9 (A), total and phospho-Akt–
Ser473 (B), CDK5 (C), p25 (D), total and phospho-ERK1/2 (E), total and
phosphor-Tau–Ser199 (F), PHF-tau (G) and β-actin antibodies as indicated. Bars are
the means ± SD of six mice. ⁎⁎P b 0.01 and ⁎P b 0.05 vs. wild type mice. Dividing
lines indicate grouping of images from different parts of the same gel.cess of unlabeled NF-κB oligonucleotide. NF-κB binding activity in-
creased in cortex nuclear extracts from PPARβ/δ-deﬁcient mice com-
pared to wild-type mice. Adding the antibody against the p65 subunit
of NF-κB led to a reduction in the intensity of the bands, whereas the
antibody against Oct-1 did not, indicating that these bands contained
the p65 subunit.
3.4. Increased GFAP protein levels in the cortex of PPARβ/δ-deﬁcient mice
In the central nervous system (CNS) inﬂammation is mediated by
microglia cells whose activation results in the production of a diverse
range of inﬂammatory molecules [32]. Thus, we examined the in-
crease in markers for activated microglia. No changes were observed
in the protein levels of CD11b (OX42), the mRNA levels of F4/80
(Fig. 5A and B) or Iba-1 immunostaining (Fig. 5C), suggesting that
the increase in NF-κB activation observed in the cortex of PPARβ/
δ-null mice does not involve microglia activation. Astrocytes can acti-
vate themselves in central nervous system pathologies, collectively
known as reactive astrogliosis, which represents a defense mecha-
nism through an as yet not fully understood signaling pathway. In
fact, astrocytes are activated in inﬂammatory and neurodegenerative
events associated with AD [33]. Rapid activation of astrocytes occurs
under pathological conditions, and is associated with increased syn-
thesis of the intermediate ﬁlament protein GFAP. The protein levels
of GFAP increased in the cortex of PPARβ/δ−/− mice compared to
wild type animals (Fig. 5D and E), suggesting that the deﬁciency of
this nuclear receptor induces astrogliosis.
3.5. Tau hyperphosphorylation in the cortical tissue of PPARβ/δ-null mice
Since tau hyperphosphorylation is one of the earliest events
detected in the brains of patients with AD [34], we then examined
the phosphorylation status of this protein. PPARβ/δ-null mice showed
hyperphosphorylation of tau at Ser199 site and a 2-fold increase
(P b 0.05) in PHF-Tau (Fig. 6A and B). Several kinases, including
CDK5, ERK1/2 and GSK-3β, are responsible for the phosphorylation
of tau [8–10]. Surprisingly, the levels of phospho-GSK3β–Ser9
increased (7-fold induction, P b 0.01) in the cortex of PPARβ/δ−/−
mice compared to wild-type animals (Fig. 6C). Since GSK3β activity
is inhibited by phosphorylation at this site [35], this ﬁnding indicates
that PPARβ/δ deﬁciency results in a reduction of the activity of this ki-
nase. In contrast, phospho-Akt levels were unchanged (Fig. 6D),
which would suggest that involvement of this kinase in the enhanced
phosphorylation of GSK-3β is unlikely. Regarding CDK5, we observed
a 3-fold induction (P b 0.05) in the protein levels of this kinase
(Fig. 6E). CDK5 is activated by its association with the activator p25
[36] and, in agreement with the enhanced levels of CDK5, we ob-
served a 7-fold increase in the protein levels of p25 in the cortex of
PPARβ/δ-deﬁcient mice compared to wild type animals (Fig. 6F). In
the cortex of PPARβ/δ-deﬁcient mice we also observed an increase
(2.5-fold induction, P b 0.01) in the phospho-ERK1/2 protein levels
(Fig. 6G).
4. Discussion
PPARs are well studied for their peripheral physiological and patho-
logical impact, but recently it has been reported that they also play a role
in the pathogenesis of AD (for review see [37]). Thus, PPARγ agonists
have been shown to reduce inﬂammatory responses in several animal
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loid burden in transgenic mice expressing mutant forms of human APP
[37,38]. However, the role of PPARβ/δ, which is expressed at higher
levels in the brain than PPARγ [39,40], on the amyloidogenic pathway
and tau hyperphosphorylation has scarcely been explored through the
use of PPARβ/δ agonists [24,41]. Here, we used PPARβ/δ-null mice to ex-
plore the effects of the deﬁciency of this nuclear receptor on these path-
ways. Our ﬁndings show that cognitive impairment present in these
mice was associated with enhanced NF-κB DNA-binding activity in the
cortex and an increased expression of cytokines, such as IL-6, which
are under the control of this transcription factor. These ﬁndings are in
agreement with a previous study showing that a PPARβ/δ agonist
prevented streptozotocin-induced neurodegeneration and ameliorated
cognitive impairment, at least in part, by reducing inﬂammation and ox-
idative stress [41]. Overall, theseﬁndings conﬁrm that PPARβ/δ prevents
inﬂammation in the cortex.
Interestingly, we found an increase in the levels of phospho-ERK1/2,
which has been reported to activate the NF-κB pathway [31,42]. In fact,
we have previously reported a similar increase in phospho-ERK1/2
levels in white adipose tissue from PPARβ/δ-deﬁcient mice and that
the PPARβ/δ agonist GW501516 prevented LPS-induced NF-κB activa-
tion in adipocytes by inhibiting ERK1/2phosphorylation [31]. Therefore,
increased ERK1/2 activation could also be responsible for the increase in
NF-κB activity in the cortex of PPARβ/δ−/−mice.
Astrocytes contribute to a variety of functions within the CNS, in-
cluding the inﬂammatory response [43]. Activation of these astro-
cytes, as measured by GFAP, increases progressively with age [44],
which has been interpreted as a reduction in their neuroprotective
capacity, thereby contributing to age-related pathology [45]. In fact,
several reports have shown increased GFAP in AD patients compared
to non-demented cases [46–48]. PPARβ/δ-deﬁcient mice showed in-
creased levels of GFAP, which is consistent with the reported reduc-
tion in astrocyte activation in the 5xFAD mice observed following
treatment with the PPARβ/δ agonist GW0742 [24]. Therefore, these
ﬁndings suggest that PPARβ/δ prevents astrocyte activation, which
can result in a reduction in inﬂammation and neurodegenerative
events related to Alzheimer's-type pathology. In contrast, it seems
that inﬂammation in the cortex of PPARβ/δ-null mice is not the result
of activation of the microglia, the resident macrophages of the CNS,
since no changes were observed in the levels of their markers.
Inﬂammation plays a role in amyloidogenesis and Aβ deposition. In
fact, several cytokines increase the generation of Aβ1–40 and Aβ1–42
peptides [49]. The relationship between these processes may rely on
two proteins involved in Aβ synthesis and deposition, which are
under the control of the pro-inﬂammatory transcription factor NF-κB,
BACE1 [19] and RAGE [20]. Interestingly, PPARβ/δ-deﬁcient mice
showed enhanced protein levels of BACE1 and RAGE in the cortex,
suggesting that PPARβ/δ activation might reduce their contribution to
amyloidogenesis and Aβ deposition during the development of AD.
Consistent with this, it has been reported that the PPARβ/δ agonist
GW0742 signiﬁcantly reduced the amyloid plaque burden in the
subiculum of 5xFAD mice [24], which overexpress APP and presenilin
1, display plaques and inﬂammation, and develop neuronal damage
and cognitive impairment. In addition to this anti-inﬂammatory effect
of PPARβ/δ, the control of BACE1 levels by PPARβ/δmight also involve
a direct action of this nuclear receptor on the promoter region of
Bace1, since it has been reported that a peroxisome proliferator re-
sponse element (PPRE) is present in the promoter region of the Bace1
gene. Although the binding of PPARγ to this PPRE represses Bace1 ex-
pression [50], it is presently unknown whether PPARβ/δ binds to this
PPRE and regulates Bace1 transcript levels.
Hyperphosphorylation of tau impairs its biological activity, induces
conformational changes, and promotes the formation of PHF, which is
the principal component of NFTs [51]. When we examined several ki-
nases involved in tau phosphorylation in the cortex of PPARβ/δ-null
mice we found enhanced levels of GSK-3β phosphorylated at Ser9(inactive). In contrast, the levels of phospho-ERK1/2 and CDK5were en-
hanced, suggesting that these kinases could be responsible for the in-
crease in tau phosphorylation at Ser199 observed in the cortex of
PPARβ/δ-deﬁcientmice. In fact, it has been reported that ERK1/2 induces
tau hyperphosphorylation in neuroblastoma cells [52,53] and brain tis-
sues [54]. In addition, increased tauphosphorylation in apoE4 transgenic
mice was associated with ERK1/2 activation [55]. Since PPARβ/δ-
deﬁciency results in increased phospho-ERK1/2 levels in the cortex, as
well as in white adipose tissue [31] and liver [56], we speculate that
the increased activity of this MAP kinase is responsible for the changes
observed in the other two tau kinases studied, GSK-3β and CDK5.
Thus, a negative crosstalk has been reported between ERK1/2 and
GSK3β [57], suggesting that the increase in the activity of the former
could be responsible for the inactivation of the latter. In addition, it has
been reported that ERK1/2 activation results in raised CDK5 levels in
neuroblastomacells [58]. Thus, although theunderlyingmechanisms re-
sponsible for these changes observed are still unknown, PPARβ/δ deﬁ-
ciency would result in enhanced ERK1/2 activity in the cortex, which
in turn could be responsible for inﬂammation, speciﬁcally increased
NF-κB activity, and tau hyperphosphorylation. If this association is con-
ﬁrmed in the cortex, targeting ERK1/2 might be a potential mechanism
for reducing both processes involved in AD pathology. Since the
PPARβ/δ-null mice is not a model for AD, additional studies should be
performed to know the involvement of this nuclear receptor in this dis-
ease by crossing these mice with a genetically modiﬁed model for AD
and to examine whether the lack of PPARβ/δ exacerbates the disease.
In summary, our ﬁndings in the cortex of PPARβ/δ-null mice indi-
cate that PPARβ/δ offers protection against inﬂammation, BACE1 and
RAGE induction, and tau hyperphosphorylation, making this nuclear
receptor a potential drug target for the treatment of AD.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2013.03.006.Acknowledgements
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